Perspectives From Patients and Gastroenterologists on De-escalating Therapy for Crohn’s Disease-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Perspectives From Patients and Gastroenterologists on De-escalating Therapy for Crohn’s Disease

Published:2021-02 Issue:2 Volume:19 Page:403-405
ISSN:1542-3565
Container-title:Clinical Gastroenterology and Hepatology
language:en
Short-container-title:Clinical Gastroenterology and Hepatology

Author:

Siegel Corey A.,Thompson Kimberly D.,Walls Danielle,Gollins Jan,Buisson Anne,Olympie Alain,Beaugerie Laurent,Colombel Jean-Frederic,Louis Edouard

Funder

Horizon 2020

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference8 articles.

1. Infliximab, azathioprine, or combination therapy for Crohn's disease;Colombel;N Engl J Med,2010

2. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial;D'Haens;Lancet,2008

3. Anti-tumor necrosis factor-alpha monotherapy versus combination therapy with an immunomodulator in IBD;Dulai;Gastroenterol Clin North Am,2014

4. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis;Siegel;Clin Gastroenterol Hepatol,2009

5. Systematic review of effects of withdrawal of immunomodulators or biologic agents from patients with inflammatory bowel disease;Torres;Gastroenterology,2015

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Management of Crohn’s disease in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease updated in 2023;Intestinal Research;2024-07-31

2. Pediatric IBD Patients Treated With Infliximab and Proactive Drug Monitoring Benefit From Early Concomitant Immunomodulatory Therapy: A Retrospective Analysis of a 10-Year Real-Life Cohort;Inflammatory Bowel Diseases;2023-11-27

3. De-escalation of Biologic Treatment in Inflammatory Bowel Disease: A Comprehensive Review;Journal of Crohn's and Colitis;2023-11-01

4. Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial;The Lancet Gastroenterology & Hepatology;2023-03

5. ECCO Topical Review on Biological Treatment Cycles in Crohn’s Disease;Journal of Crohn's and Colitis;2023-01-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3